Immunogenetic and molecular biomarkers in COVID-19 and hepatitis C virus infection: Evaluating the diagnostic potential of HLA (rs1131500), IGF-2, and I-FABP

Read full text Summarise with VIRAT
Authors: Amal Ahmed Mohamed, Rasha M. Abdel Hamid, Amr Amin, Eman Al Hussain A. Gawad, Salma Mohamed Saed, Dalia Ali Gaber, M. Arab, Waleed El Agawy, Mohammed Zakaria Ali AbuRahma, Heba Elosaily, Elsaeed E. Shaaban, Shaymaa A. Ismail
+1 more Amany A. Sakr
Cited by: 0
References: 57

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND The human leukocyte antigen (HLA) system represents one of the most genetically diverse and densely packed genomic regions, playing a fundamental role in orchestrating immune responses. Among molecular markers linked to viral pathogenesis and immune modulation are insulin-like growth factor 2 (IGF-2) and intestinal fatty-acid-binding protein (I-FABP). AIM To investigate the influence of the HLA variant rs1131500, together with IGF-2 and I-FABP, on susceptibility to hepatitis C virus (HCV), coronavirus disease 2019 (COVID-19), and their co-occurrence, to identify predictive biomarkers and potential therapeutic targets. METHODS The study involved quantifying circulating levels of IGF-2, I-FABP, and interferon-gamma (IFN-γ) and genotyping HLA rs1131500 using real-time polymerase chain reaction. Participants provided nasopharyngeal swabs for detection of severe acute respiratory syndrome coronavirus 2 RNA and blood samples for HCV RNA analysis and biomarker assessment. RESULTS Levels of IGF-2 and I-FABP were notably higher in all patient categories, with the highest values observed in co-infected individuals (P < 0.0001). A moderate positive correlation was observed between I-FABP and IFN-γ in COVID-19 cases (r = 0.261, P = 0.05). IGF-2 had the most substantial predictive value (odds ratio [OR]: 4.5-5.5), while IFN-γ showed a protective trend (OR < 1) when combined with IGF-2 and I-FABP. CONCLUSION IGF-2 emerged as the most consistent and reliable biomarker across all patient groups, particularly in COVID-19 and co-infections. I-FABP was a strong marker for co-infection, less so for COVID-19, and ineffective for HCV alone. Genetically, the CC genotype was more common in the HCV and Control groups, whereas the TT genotype was associated with COVID-19 and co-infection, suggesting potential diagnostic value.

Fields of Study & Subjects

Hepatitis C virus research Genetic Associations and Epidemiology COVID-19 Clinical Research Studies

Publication details

Journal / source
World Journal of Hepatology
Volume
18
Issue
3
Publication date
26 March 2026
Language
EN